Literature DB >> 24032592

Studies on the inactivation of human parvovirus 4.

Sally A Baylis1, Philip W Tuke, Eiji Miyagawa, Johannes Blümel.   

Abstract

BACKGROUND: Human parvovirus 4 (PARV4) is a novel parvovirus, which like parvovirus B19 (B19V) can be a contaminant of plasma pools used to prepare plasma-derived medicinal products. Inactivation studies of B19V have shown that it is more sensitive to virus inactivation strategies than animal parvoviruses. However, inactivation of PARV4 has not yet been specifically addressed. STUDY DESIGN AND METHODS: Treatment of parvoviruses by heat or low-pH conditions causes externalization of the virus genome. Using nuclease treatment combined with real-time polymerase chain reaction, the extent of virus DNA externalization was used as an indirect measure of the inactivation of PARV4, B19V, and minute virus of mice (MVM) by pasteurization of albumin and by low-pH treatment. Infectivity studies were performed in parallel for B19V and MVM.
RESULTS: PARV4 showed greater resistance to pasteurization and low-pH treatment than B19V, although PARV4 was not as resistant as MVM. There was a 2- to 3-log reduction of encapsidated PARV4 DNA after pasteurization and low-pH treatment. In contrast, B19V was effectively inactivated while MVM was stable under these conditions. Divalent cations were found to have a stabilizing effect on PARV4 capsids. In the absence of divalent cations, even at neutral pH, there was a reduction of PARV4 titer, an effect not observed for B19V or MVM.
CONCLUSION: In the case of heat treatment and incubation at low pH, PARV4 shows intermediate resistance when compared to B19V and MVM. Divalent cations seem important for stabilizing PARV4 virus particles.
© 2013 American Association of Blood Banks.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24032592     DOI: 10.1111/trf.12372

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  4 in total

Review 1.  Human Parvovirus B19 and blood product safety: a tale of twenty years of improvements.

Authors:  Giuseppe Marano; Stefania Vaglio; Simonetta Pupella; Giuseppina Facco; Gabriele Calizzani; Fabio Candura; Giancarlo M Liumbruno; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2015-04       Impact factor: 3.443

Review 2.  Human parvovirus 4 'PARV4' remains elusive despite a decade of study.

Authors:  Philippa C Matthews; Colin Sharp; Peter Simmonds; Paul Klenerman
Journal:  F1000Res       Date:  2017-01-27

3.  Transfusion-transmitted emerging infectious diseases: 30 years of challenges and progress.

Authors:  Susan L Stramer; Roger Y Dodd
Journal:  Transfusion       Date:  2013-08-09       Impact factor: 3.157

4.  Identification of human parvovirus 4 genotypes 1 and 2 in Chinese source plasma pools.

Authors:  Junting Jia; Yadi Zhong; Huan Zhang; Dian Yuan; Limin Ma; Deqing Wang; Jingang Zhang; Yuyuan Ma
Journal:  J Med Virol       Date:  2021-03-14       Impact factor: 2.327

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.